Pharmacophore an International Research Journal
With the increasing in pressure of healthcare costs all the large innovator companies as well as Indian MNCs drive up their business in generic market. In this context, markets like India are especially attractive, given their potential for higher growth. The pharma industry in India has over the last few years have seen some large inorganic investments by pharma MNCs and these acquisitions are likely to play a significant role in expanding the generic footprints of the MNCs concerned both in India and in other major markets. Moving forward, most pharma MNCs are likely to maintain their focus on the Indian market, strengthening their product basket and sales network.
